F11

2

N,N,N-Trimethyl-4-(2-oxoborn-3-ylidenemethyl) anilinium methyl sulfate

Camphor Benzalkonium Methosulfate

52793-97-2

258-190-8

6 %

3

Benzoic acid, 2-hydroxy-, 3,3,5-trimethylcyclohexyl ester/Homosalate

Homosalate

118-56-9

204-260-8

10 %

F74

2-Hydroxy-4-methoxybenzophenone/Oxybenzone

Benzophenone-3

131-57-7

205-031-5

6 %

Not more than 0,5 % to protect product formulation

Contains Benzophenone-383

5

Moved or deleted

6

2-Phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts/Ensulizole

Phenylbenzimidazole Sulfonic Acid

27503-81-7

248-502-0

8 %(as acid)

7

3,3'-(1,4-Phenylenedimethylene) bis(7, 7-dimethyl-2-oxobicyclo-[2.2.1]hept-1-yl-methanesulfonic acid) and its salts/Ecamsule

Terephthalylidene Dicamphor Sulfonic Acid

92761-26-7, 90457-82-2

410-960-6

10 %(as acid)

8

1-(4-tert-Butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione/Avobenzone

Butyl Methoxydibenzoylmethane

70356-09-1

274-581-6

5 %

9

alpha-(2-Oxoborn-3-ylidene)-toluene-4-sulphonic acid and its salts

Benzylidene Camphor Sulfonic Acid

56039-58-8

6 % (as acid)

10

2-Cyano-3,3-diphenyl acrylic acid, 2-ethylhexyl ester/Octocrilene

Octocrylene

6197-30-4

228-250-8

10 % (as acid)

11

Polymer of N-{(2 and 4)-[(2-oxoborn-3-ylidene)methyl]benzyl} acrylamide

Polyacrylamidomethyl Benzylidene Camphor

113783-61-2

6 %

12

2-Ethylhexyl 4-methoxycinnamate/Octinoxate

Ethylhexyl Methoxycinnamate

5466-77-3

226-775-7

10 %

13

Ethoxylated ethyl-4-aminobenzoate

PEG-25 PABA

116242-27-4

10 %

14

Isopentyl-4-methoxycinnamate/Amiloxate

Isoamyl p-Methoxycinnamate

71617-10-2

275-702-5

10 %

15

2,4,6-Trianilino-(p-carbo-2'-ethylhexyl-1'-oxy)-1,3,5-triazine

Ethylhexyl Triazone

88122-99-0

402-070-1

5 %

16

Phenol,2-(2H-benzotriazol-2-yl)-4-methyl-6-(2-methyl-3-(1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy)-disiloxanyl)propyl)

Drometrizole Trisiloxane

155633-54-8

15 %

17

Benzoic acid, 4,4-((6-((4-(((1,1-dimethylethyl)amino)carbonyl)phenyl)amino)-1,3,5-triazine-2,4-diyl)diimino)bis-, bis (2-ethylhexyl) ester/Iscotrizinol (USAN)

Diethylhexyl Butamido Triazone

154702-15-5

10 %

18

3-(4-Methylbenzylidene)-d1 camphor/Enzacamene

4-Methylbenzylidene Camphor

38102-62-4/36861-47-9

- / 253-242-6

4 %

F8

20

2-Ethylhexyl salicylate/Octisalate

Ethylhexyl Salicylate

118-60-5

204-263-4

5 %

21

2-Ethylhexyl 4-(dimethylamino)benzoate/Padimate O (USAN:BAN)

Ethylhexyl Dimethyl PABA

21245-02-3

244-289-3

8 %

22

2-Hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt/Sulisobenzone

Benzophenone-4, Benzophenone-5

4065-45-6/6628-37-1

223-772-2 / -

5 % (as acid)

F923

2,2′-Methylene- bis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)/Bisoctrizole

Methylene Bis-Benzotriazolyl Tetramethylbutylphenol

103597-45-1

403-800-1

10 % 87

F623a

2,2′-Methylene- bis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)/Bisoctrizole

Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (nano)

103597-45-1

403-800-1

10 % 87

Not to be used in applications that may lead to exposure of the end user's lungs by inhalation.

Only nanomaterials having the following characteristics are allowed:

• Purity ≥ 98,5 %, with 2,2′-methylene-bis-(6(2H-benzotriazol-2-yl)-4-(isooctyl)phenol) isomer fraction not exceeding 1,5 %;

• Solubility < 5 ng/L in water at 25 °C;

• Partition coefficient (Log Pow): 12,7 at 25 °C;

• Uncoated;

• Median particle size D50 (50 % of the number below this diameter): ≥ 120 nm of mass distribution and/or ≥ 60 nm of number size distribution.

24

Sodium salt of 2,2'-bis(1,4-phenylene)-1H-benzimidazole-4,6-disulfonic acid) / Bisdisulizole disodium (USAN)

Disodium Phenyl Dibenzimidazole Tetrasulfonate

180898-37-7

429-750-0

10 % (as acid)

25

2,2'-(6-(4-Methoxyphenyl)-1,3,5-triazine-2,4-diyl)bis(5-((2-ethylhexyl)oxy)phenol) / Bemotrizinol

Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine

187393-00-6

10 %

26

Dimethicodiethylbenzalmalonate

Polysilicone-15

207574-74-1

426-000-4

10 %

F327

Titanium dioxide 84

Titanium Dioxide

13463-67-7/

1317-70-0/

1317-80-2

236-675-5/

215-280-1/

215-282-2

25 % 86

F1027a

Titanium dioxide 84

Titanium Dioxide (nano)

13463-67-7/1317-70-0/1317-80-2

236-675-5/215-280-1/215-282-2

25 % 86

Not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation.

Only nanomaterials having the following characteristics are allowed:

• purity ≥ 99 %,

• rutile form, or rutile with up to 5 % anatase, with crystalline structure and physical appearance as clusters of spherical, needle, or lanceolate shapes,

• median particle size based on number size distribution ≥ 30 nm,

• aspect ratio from 1 to 4,5, and volume specific surface area ≤ 460 m ² /cm ³ ,

• coated with Silica, Hydrated Silica, Alumina, Aluminium Hydroxide, Aluminium Stearate, Stearic Acid, Trimethoxycaprylylsilane, Glycerin, Dimethicone, Hydrogen Dimethicone, Simethicone,

or coated with one of the following combinations:

• Silica at a maximum concentration of 16 % and Cetyl Phosphate at a maximum concentration of 6 %,

• Alumina at a maximum concentration of 7 % and Manganese Dioxide at a maximum concentration of 0,7 % (not to be used in lip products),

• Alumina at a maximum concentration of 3 % and Triethoxycaprylylsilane at a maximum concentration of 9 %,

• photocatalytic activity ≤ 10 % compared to corresponding non-coated or non-doped reference,

• nanoparticles are photostable in the final formulation.

For face products containing Titanium Dioxide (nano) coated with the combination Alumina and Manganese Dioxide:

Not to be used on the lips.

F128

Benzoic acid, 2-[-4-(diethylamino)-2-hydroxybenzoyl]-. Hexylester

Diethylamino Hydroxy benzoyl Hexyl Benzoate

302776-68-7

443-860-6

10  %

F2X129

1,3,5-Triazine, 2,4,6-tris[1,1'-biphenyl]-4-yl-, including as nanomaterial

Tris-biphenyl triazine

Tris-biphenyl triazine (nano)

31274-51-8

—

10 %

Not to be used in sprays.

Only nanomaterials having the following characteristics are allowed:

• median primary particle size > 80 nm;

• Purity ≥ 98 %;

• Uncoated

F430

Zinc oxide

Zinc Oxide

1314-13-2

215-222-5

25 % 85

Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation.

30a

Zinc oxide

Zinc Oxide (nano)

1314-13-2

215-222-5

25 % 85

Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation.

Only nanomaterials having the following characteristics are allowed:

• purity ≥ 96 %, with wurtzite crystalline structure and physical appearance as clusters that are rod-like, star-like and/or isometric shapes, with impurities consisting only of carbon dioxide and water, whilst any other impurities are less than 1 % in total,

• median diameter of the particle number size distribution D50 (50 % of the number below this diameter) > 30 nm and D1 (1 % below this size) > 20 nm,

• water solubility < 50 mg/L

• uncoated, or coated with triethoxycaprylylsilane, dimethicone, dimethoxydiphenylsilanetriethoxycaprylylsilane cross-polymer, or octyl triethoxy silane.

F1131

3,3′-(1,4-Phenylene)bis(5,6-diphenyl-1,2,4-triazine)

Phenylene Bis-Diphenyltriazine

55514-22-2

700-823-1

5 %

Not to be used in applications that may lead to exposure of the end user's lungs by inhalation.

F1232

2-ethoxyethyl (2Z)-2-cyano-2-[3-(3-methoxypropylamino) cyclohex-2-en-1-ylidene]acetate

Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate

1419401-88-9

700-860-3

3 %

• Not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation

• Do not use with nitrosating agents – Maximum nitrosamine content: 50 μg/kg

• Keep in nitrite-free containers

F1333

1,1’-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone

Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine

919803-06-8

485-100-6

10%

In case of combined use of Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine and Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano), the sum shall not exceed 10  %.

F1334

1,1’-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone

Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano)

919803-06-8

485-100-6

10%

Only anomaterials having the following characteristics are allowed:

• Purity ≥ 97 %,

• Median particle size D50 (50 % of the number below this diameter): ≥ 50 nm of number size distribution.

Not to be used in applications that may lead to exposure of the end user’s lungs by inhalation.

In case of combined use of Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine and Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano), the sum shall not exceed 10  %.